mTOR inhibition in management of advanced breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The mechanistic target of rapamycin (mTOR) pathway plays a significant role in cell growth, proliferation, and survival.
• Dysregulation of the mTOR pathway is implicated in the development and progression of various cancers, including breast cancer.
• Understanding the mTOR pathway's function is vital for developing targeted cancer therapies.

Purpose of the Study:

• To review the role of mTOR pathway inhibition in the management of advanced breast cancer.
• To summarize current therapeutic strategies targeting the mTOR pathway for breast cancer treatment.
• To discuss the clinical implications and future directions of mTOR inhibitors in advanced breast cancer.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of data from clinical trials investigating mTOR inhibitors in advanced breast cancer.
• Synthesis of evidence on the efficacy and safety of mTOR inhibition.

Main Results:

• mTOR pathway activation is frequently observed in advanced breast cancer.
• Inhibition of the mTOR pathway has demonstrated clinical activity in subsets of patients with advanced breast cancer.
• Specific mTOR inhibitors show varying degrees of efficacy depending on the breast cancer subtype and prior treatments.

Conclusions:

• Targeting the mTOR pathway represents a viable therapeutic strategy for advanced breast cancer.
• Further research is needed to identify predictive biomarkers and optimize treatment regimens for mTOR inhibitors.
• mTOR pathway inhibition holds potential for improving outcomes in patients with advanced breast cancer.